Holen Sie sich die Stockscreener-App
1.52
1.33%
0.02
Schlusskurs vom Vortag:
$1.50
Offen:
$1.51
24-Stunden-Volumen:
1,203
Relative Volume:
0.00
Marktkapitalisierung:
$81.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.16M
KGV:
-0.5118
EPS:
-2.97
Netto-Cashflow:
$-130.08M
1W Leistung:
+3.40%
1M Leistung:
+14.29%
6M Leistung:
+142.81%
1J Leistung:
-0.65%
1-Tages-Spanne:
$1.50
$1.51
1-Wochen-Bereich:
$1.3901
$1.56
52-Wochen-Spanne:
$0.404
$2.27
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALXO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.50 | 80.24M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.83 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.22 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
861.17 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
352.00 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.51 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-06 | Eingeleitet | UBS | Buy |
| 2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-11 | Eingeleitet | Jefferies | Buy |
| 2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
IPO Launch: Is ALX Oncology Holdings Inc affected by consumer sentimentPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
VIX Spike: Is ALX Oncology Holdings Inc in accumulation or distribution phase2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn
Investment Report: Will ALX Oncology Holdings Inc stock hit new highs in YEARIPO Watch & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ALX Oncology increases shares reserved for inducement equity plan By Investing.com - Investing.com Nigeria
ALX Oncology increases shares reserved for inducement equity plan - Investing.com
ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks
Aug Volume: How does QuantumScape Corporation correlate with NasdaqEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Highs Report: Does ALX Oncology Holdings Inc. have high return on assetsJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - bollywoodhelpline.com
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference - MarketBeat
ALX Oncology : Investor Presentation ALX presentation at JPM 2026 12Jan2026 FINAL (698186) - marketscreener.com
Aug Spikes: Will ALX Oncology Holdings Inc stock recover after earnings - baoquankhu1.vn
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks - Yahoo Finance
Stock Report: Why ALX Oncology Holdings Inc stock remains undervaluedPortfolio Performance Summary & AI Enhanced Trading Alerts - Bộ Nội Vụ
Is ALX Oncology Holdings Inc. stock trading near support levelsJuly 2025 Fed Impact & Weekly Top Performers Watchlists - Улправда
Hedge Fund Moves: How geopolitical tensions affect ALX Oncology Holdings Inc. stockJuly 2025 Update & Consistent Profit Trading Strategies - Улправда
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Why ALX Oncology Holdings Inc. stock remains undervaluedWeekly Market Report & Daily Momentum Trading Reports - Улправда
How ALX Oncology Holdings Inc. stock compares to market leadersJuly 2025 Momentum & Safe Capital Growth Stock Tips - Улправда
How geopolitical tensions affect ALX Oncology Holdings Inc. stock2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
ALX Oncology Advances Separate Clinical Trials Evaluating - GlobeNewswire
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Meme Stocks: Will ALX Oncology Holdings Inc stock deliver consistent dividends2025 Valuation Update & Weekly Market Pulse Updates - moha.gov.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0% - Defense World
ALXOAmended Statement of Beneficial Ownership (3/a) - ADVFN
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights - ADVFN
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ADVFN
ALX Oncology (NASDAQ:ALXO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Aug PostEarnings: What technical charts say about ALX Oncology Holdings Inc. stock2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - DonanımHaber
What momentum indicators show for ALX Oncology Holdings Inc. stockMarket Risk Summary & AI Driven Price Forecasts - Улправда
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
ALX Oncology (NASDAQ:ALXO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Alx Oncology rallies on strong phase 2 data for lymphoma therapy - MSN
Alx Oncology stock soars after impressive lymphoma treatment results By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025 - Kalkine Media
ALXO: Promising Phase 2 Trial Results for Evorpacept in iNHL Tre - GuruFocus
Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymph - marketscreener.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Sahm
ALX Oncology (NASDAQ: ALXO) hits 92% CR, 100% ORR in Phase 2 iNHL combo trial - Stock Titan
ALX Oncology (NASDAQ:ALXO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3.8%Here's Why - MarketBeat
Reviewing Harmony Biosciences (NASDAQ:HRMY) and ALX Oncology (NASDAQ:ALXO) - Defense World
Why ALX Oncology Holdings Inc. stock could benefit from AI revolutionMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight - GlobeNewswire
How resilient is ALX Oncology Holdings Inc. stock in market downturnsMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alx Oncology Holdings Inc-Aktie (ALXO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
0.82%
4.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):